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TO THE EDITOR
Alopecia areata (AA) is a common hair-
loss disorder that affects approximately
1–2% of the general population
(Safavi et al., 1995). The occurrence
of familial AA is well established
(Blaumeiser et al., 2006), and the
pattern of familiality strongly suggests
that its genetic basis is multifactorial.
Our current understanding of the etio-
pathogenesis of AA is incomplete, but
the condition is thought to be a tissue-
specific autoimmune disease directed
against the hair follicle (Tobin, 2003).
Numerous studies in the past
decade have reported an association
between variants of the gene coding for
the cytotoxic T lymphocyte antigen-4
(CTLA4) and some of the autoimmune
diseases, including Graves’ disease,
antineutrophil cytoplasmic antibo-
dy–associated vasculitis, type 1 dia-
betes, and rheumatoid arthritis
(Kristiansen et al., 2000; Ueda et al.,
2003). CTLA4 is a costimulatory
molecule that is expressed on activated
T cells and is involved in the negative
regulation of T-cell activation (Brunet
et al., 1987). Given the autoimmune
component shared by the various
autoimmune diseases, we aimed to
investigate the role of CTLA4 in the
development of AA. We performed a
high-resolution association analysis
of the CTLA4 gene locus using 22
tagging single-nucleotide polymorph-
isms (SNPs) in a sample of 1,196
unrelated AA patients and 1,280 con-
trols of Central European origin. During
the final preparation of this report, a
genome-wide association study was
published by Petukhova et al. (2010)
that implicates several new gene loci
for AA, including CTLA4.
In our study, eight variants showed
nominal significance in the combined
sample (Table 1). The strongest associa-
tion was found for rs3087243, which is
located 236 bp downstream of CTLA4
(Figure 1). This had a nominal P-value
(Pnom) of 4.66107 and an odds ratio
Abbreviations: AA, alopecia areata; CTLA4, cytotoxic T lymphocyte antigen-4; OR, odds ratio;
SNP, single-nucleotide polymorphism
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(OR) of 1.34 (95% confidence interval:
1.20–1.50) (Table 1). In total, six of the
eight nominally significant SNPs with-
stood Bonferroni correction for multiple
testing (Table 1). Genotype distributions
are shown in Supplementary Table S1
online.
In the subgroup analyses, the highest
ORs were observed among the follow-
ing groups of cases: (i) severe, (ii) early
age at onset, and (iii) positive family
history (Table 1). The highest OR was
observed in the severe group for
rs1427678, which is located approxi-
mately 20 kb downstream of CTLA4
(Pnom¼6.38 1010; OR¼ 1.55 (1.35–
1.78)). In the analysis of only mild
cases, one marker (rs3087243) showed
a significant (Pnom¼0.03) association,
although this result did not withstand
correction for multiple testing (data not
shown).
We then performed a conditional
association analysis of the combined
sample to test whether the most strongly
associated marker (rs1427678) alone
was able to explain the associ-
ation signal observed at this locus. In
this analysis, one additional SNP
(rs11571290) showed nominal signifi-
cance (Pnom¼0.017) after accounting
for rs1427678. However, when the
conditional analysis was restricted to
the severely affected cases, rs1427678
explained the whole association
signal, with no additional effect from
other SNPs.
We also investigated which of the
clinical covariates contributed indepen-
dently to the association. Severity,
in combination with rs1427678, sig-
nificantly improved the fit of a logistic
model (P¼5.98 107). The other
covariates did not improve the model
fit (e.g., P¼ 0.15 for early age at onset).
A haplotype analysis did not signifi-
cantly improve the association findings
(data not shown).
Our findings and the findings by
Petukhova et al. (2010) provide strong
evidence for the association of CTLA4
with AA, and indicate that the CTLA4
locus might be a genetic factor that is
shared between AA and other autoim-
mune diseases. We observed the
strongest effect in patients with severe
disease, as observed previously for
other AA susceptibility genes (Betz
et al., 2007, 2008; Redler et al.,
2010). The usefulness of the severity
criterion in defining the group of
patients that drives the association
is demonstrated by the results of the
logistic regression analysis. In this
analysis, inclusion of other covariates,
such as age at onset and familiality,
yielded no significant improvement in
the association finding (Table 1).
Our results revealed that rs3087243
was the best of the 21 analyzed
SNPs in the combined sample, with a
corrected P-value of 4.89 105
(OR¼1.34 (1.20–1.50)). This is the
most consistently implicated SNP in
other autoimmune diseases. The size of
the genetic effect observed in our
sample is comparable to that observed
for other autoimmune diseases (Ueda
et al., 2003; Plenge et al., 2005).
However, the functional impact of
this variant, which is located in the 30
untranslated region of CTLA4, remains
unclear. It has been suggested that this
variant may affect the expression of
CTLA4, given that decreased levels of
soluble CTLA4 have been observed in
carriers of the susceptibility allele
(Ueda et al., 2003; Maier et al., 2007).
However, the present findings cannot
exclude the possibility that a variant
that is in linkage disequilibrium with
rs3087243 is the true causative variant.
Petukhova et al. (2010) found the
strongest association for rs1024161, a
SNP that was not examined in our
study. The variant rs3087243 was not
genotyped in their study, but, based on
imputation, it too showed a highly
significant association.
The SNP rs231775 is the only
validated nonsynonymous SNP in the
coding region of CTLA4. The results of
in vitro studies have shown that the
amino-acid substitution p.Thr17Ala in
the signal peptide of CTLA4 causes
defective endoplasmic reticulum
processing of a significant portion of
the susceptibility allele molecules
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Figure 1. Details of the investigated genomic region (204 402596–204 498096 bp; NCBI reference
sequence build 36) on chromosome 2. (a) Transcript information for the investigated cytotoxic
T lymphocyte antigen-4 (CTLA4) locus (UCSC Genome Browser, build 36), with arrows indicating
the direction of transcription. (b) Negative log10 association P-values of markers analyzed in the
case–control study. (c) Linkage disequilibrium (LD) at the CTLA4 locus is displayed by r2. LD and
haplotype blocks were analyzed using Haploview software (version 4.1).
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CTLA4 in Alopecia Areata
(CTLAAla17) and that this results in
inefficient glycosylation and decreased
cell-surface expression (Anjos et al.,
2002). Our association results show that
rs231775 was also strongly associated
with AA in our sample although the
P-values were less significant and
the ORs were lower than those for
rs3087243. Furthermore, conditional
analysis revealed that rs1427678
explained the entire association signal
at the locus.
In conclusion, our results provide
strong support for the hypothesis that
CTLA4 is a susceptibility gene for AA,
and they also suggest that it has the
strongest effect in patients with a severe
form of the disorder. Given the low
P-values observed in our study and
the genome-wide association study by
Petukhova et al. (2010), we consider
CTLA4 a proven susceptibility gene
for AA.
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Erythropoietic Uroporphyria Associated with Myeloid
Malignancy Is Likely Distinct from Autosomal Recessive
Congenital Erythropoietic Porphyria
Journal of Investigative Dermatology (2011) 131, 1172–1175; doi:10.1038/jid.2011.5; published online 17 February 2011
TO THE EDITOR
Congenital erythropoietic porphyria
(CEP; MIM 263700) is a rare autosomal
recessive disease caused by muta-
tions in uroporphyrinogen III synthase
(UROS) or, rarely, in GATA1 genes,
leading to UROS deficiency (Fritsch
et al., 1997; de Verneuil et al., 2003;
Phillips et al., 2007). The resulting
overproduction of type I porphyrin
isomers by erythroid cells causes severe
photosensitivity and hemolytic anemia.
Abbreviations: BFU, burst-forming unit; CEP, congenital erythropoietic porphyria; MDS, myelodysplastic
syndrome; UROS, uroporphyrinogen III synthase
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